Endocrine Abstracts

Maintaining normal serum and urinary calcium in patients with chronic hypoparathyroidism (cHP) remains a therapeutic challenge. Parathyroid hormone (PTH) replacement therapy is not ideal due to its short half-life and transient activation of the PTH 1 receptor (PTH1R). Eneboparatide is a hybrid analog of PTH and PTH-related peptide specifically designed to induce prolonged activation of the PTH1R. Despite a short half-life, eneboparatide is able to normalize serum and urinary ...

Eneboparatide (AZP-3601) is a novel, synthetic, 36-amino-acid peptide agonist of the parathyroid hormone type 1 receptor (PTHR1), with potent selectivity for the R0 conformation. This results in prolonged calcemic responses, while having a short circulating half-life. Eneboparatide is being developed for the treatment of chronic hypoparathyroidism (cHP). Studies in hypoparathyroid animal models and, most recently, in hypoparathyroid patients, have demonstrated that eneboparati...

Medical treatment of acromegaly is based on either suppressing pituitary growth hormone (GH) secretion or by inhibiting GH action by preventing interaction with its receptor in order to suppress the elevated levels of insulin-like growth factor 1 (IGF1). AZP-3813 is a 16-amino acid, bicyclic peptide antagonist of the GH receptor (GHR) with KD of 1.9 nM for the human GHR. Previously, AZP-3813 was demonstrated to suppress IGF1 secretion in juvenile rats in a dose-rela...

While somatostatin analogs (SSA) are the primary medical therapy for treatment of acromegaly, they fail to normalize insulin-like growth factor 1 (IGF1) levels in the majority of patients when used as monotherapy. Even in patients with controlled IGF1, growth hormone (GH) levels can remain elevated and induce symptoms by interacting with GH receptors throughout the body. AZP-3813 is a 16-amino acid, bicyclic peptide GH receptor antagonist (GHRA) which has been demonstrated to ...

Background: Acromegaly is a rare disease typically caused by a benign growth hormone (GH)-secreting pituitary adenoma that stimulates over-production of insulin-like growth factor-1 (IGF1) from the liver. Treatment with somatostatin analog (SSA) monotherapy does not provide optimal control of circulating IGF-1 levels in the majority of patients. AZP-3813, a 16-amino acid, bicyclic GH receptor antagonist (GHRA) binds to the GH receptor and prevents endogenous GH from stimulatin...